Adam D Cohen, MD

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-175
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: 215-615-5853
Fax: 215-615-5887
Harvard University, 1994.
University of Pennsylvania, 1999.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

Multiple Myeloma
POEMS syndrome
Monoclonal gammopathies
Waldenstrom's Macroglobulinemia

Description of Research Expertise

Cancer immunotherapy
Cellular therapy
Phase I trials
CAR T cells

Selected Publications

Cohen AD, Garfall AL, Dogan A, Lacey SF, Martin C, Lendvai N, Vogl DT, Spear M, Lesokhin AM: Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies Blood Adv Aug 2019.

Cohen, A D., Garfall, A L., Stadtmauer, E A., Melenhorst, J. J, Lacey, Simon F., Lancaster, E, Vogl, D T., Weiss, B M., Dengel, K, Nelson, A, Plesa, G, Chen, F, Davis, M M., Hwang, Wei-Ting, Young, R M., Brogdon, J L., Isaacs, R, Pruteanu-Malinici, I, Siegel, D L., Levine, B L., June, C H., Milone, M C.: B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. The Journal of Clinical Investigation. The American Society for Clinical Investigation, Page: doi: 10.1172/JCI126397, Mar 2019.

Susanibar Adaniya, S P., Cohen, A D.*, Garfall, A L.*: Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications. American Journal of Hematology doi: 10.1002/ajh.25428, Feb 2019 Notes: co-senior authors.

Pazina T, James AM, Colby KB, Yang Y, Gale A, Jhatakia A, Kearney A, Graziano RF, Bezman NA, Robbins MD, Cohen AD, Campbell KS. : Elotuzumab enhances SLAMF7 interactions between natural killer and multiple myeloma cells to co-stimulate cytotoxicity. Cancer Immunology Research 2019 Notes: (in press).

Fajgenbaum DC, Langan R-A, Japp AS, Shilling D, Partridge HL, Pierson SK, Singh A, Ruth JR, Nabel CS, Stone K, Chaturvedi V, Okumura M, Schwarer A, Jose FF, Hamerschlak N, Wertheim GB, Cohen AD, Krymskaya V, Rubenstein A, Betts M, Kambayashi T, Jordan MB, van Rhee F, Uldrick TS. : P13K/Akt/mTOR is a Novel Therapeutic Target in IL-6-blockade Refractory iMCD. Journal of Clinical Investigation 2019.

Cornell RF, Ky B, Weiss BM, Dahm C, Gupta DK, Du L, Carver JR, Cohen AD, Engelhardt BG, Garfall AL, Goodman SA, Harrell SL, Kassim AA, Jadhav T, Jagasia M, Moslehi J, O’Quinn R, Savona MR, Slosky D, Smith Am, Stadtmauer EA, Vogl DT, Waxman A, Lenihan D. : Prospective Study of Cardiac Events during Proteastome Inhibitor Therapy for Relapsed Multiple Myeloma. Journal of Clinical Oncology 2019 Notes: (in press).

Cohen AD, Lendvai N, Nataraj S, Imai N, Jungbluth AA, Tsakos I, Rahman A, Mei AH, Singh H, Zarychta K, Kim-Schulze S, Park A, Venhaus R, Alpaugh K, Gnjatic S, Cho HJ.: Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine–Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma. Cancer Immunology Research 7(4): 658-669, 2019 Notes: co-first authors.

Trudel, S, Lendvai, N, Popat, R, Voorhees, P M., Reeves, B, Libby, E N., Richardson, P G., Hoos, A, Gupta, I, Bragulat, V, He, Z, Opalinska, J B., Cohen, A D.: Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer Journal 9(4): 37, 2019.

Garfall A, Dancy E, Cohen A, Wang WH, Frai J, Suhoski M, Levine B, Siegel D, Stadtmauer E,Vogl D, Waxman A, Rapoport A, Milone M, June C, Melenhorst J: T cell phenotypes associated with effective CAR T cell therapy in post-induction versus relapsed multiple myeloma. Blood Advances In Press 2019.

L Bernabei, A L. Garfall, J. J Melenhorst, S F Lacey, E A. Stadtmauer, D T. Vogl, V Gonzalez, G Plesa, R M Young, A Waxman, B L Levine, C H June, M C. Milone, and A D. Cohen: PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after BCMA-Directed CAR T Cells Blood, ASH Annual Meeting, San Diego, CA 132: #1973, Dec 2018 Notes: Poster.

back to top
Last updated: 01/23/2020
The Trustees of the University of Pennsylvania